Eli Lilly (LLY) Cash & Equivalents (2009 - 2026)
Eli Lilly posted quarterly Cash & Equivalents of $5.3 billion for Q1 2026, up 70.76% year-on-year from $3.1 billion in Q1 2025, and down 27.33% on a QoQ basis from $7.3 billion in Q4 2025.
Eli Lilly (LLY) has 18 years of Cash & Equivalents data on file, last reported at $5.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents rose 70.76% year-over-year to $5.3 billion; the trailing twelve-month figure through Mar 2026 stood at $5.3 billion (up 70.76% YoY), and the FY2025 full-year result was $7.3 billion, up 122.4% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $5.3 billion, down from $7.3 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $9.8 billion in Q3 2025 and bottomed at $2.1 billion in Q4 2022.
- The 5-year median for Cash & Equivalents is $3.1 billion (2025), against an average of $3.7 billion.
- The widest annual swing landed in 2022, when Cash & Equivalents plunged 45.87%; it then jumped 190.65% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $2.1 billion in 2022, then soared by 36.36% to $2.8 billion in 2023, then rose by 15.94% to $3.3 billion in 2024, then jumped by 122.4% to $7.3 billion in 2025, then decreased by 27.33% to $5.3 billion in 2026.
- The last three Cash & Equivalents figures came in at $5.3 billion (Q1 2026), $7.3 billion (Q4 2025), and $9.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 4.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.28 Bn |
| Dec 31, 2025 | 7.27 Bn |
| Sep 30, 2025 | 9.79 Bn |
| Jun 30, 2025 | 3.38 Bn |
| Mar 31, 2025 | 3.09 Bn |
| Dec 31, 2024 | 3.27 Bn |
| Sep 30, 2024 | 3.37 Bn |
| Jun 30, 2024 | 3.22 Bn |
| Mar 31, 2024 | 2.46 Bn |
| Dec 31, 2023 | 2.82 Bn |
| Sep 30, 2023 | 2.38 Bn |
| Jun 30, 2023 | 2.69 Bn |
| Mar 31, 2023 | 3.55 Bn |
| Dec 31, 2022 | 2.07 Bn |
| Sep 30, 2022 | 2.62 Bn |
| Jun 30, 2022 | 2.62 Bn |
| Mar 31, 2022 | 2.46 Bn |
| Dec 31, 2021 | 3.82 Bn |
| Sep 30, 2021 | 3.79 Bn |
| Jun 30, 2021 | 3.22 Bn |
| Mar 31, 2021 | 3.00 Bn |
| Dec 31, 2020 | 3.66 Bn |
| Sep 30, 2020 | 3.60 Bn |
| Jun 30, 2020 | 2.37 Bn |
| Mar 31, 2020 | 1.70 Bn |
| Dec 31, 2019 | 2.34 Bn |
| Sep 30, 2019 | 1.56 Bn |
| Jun 30, 2019 | 2.29 Bn |
| Mar 31, 2019 | 2.04 Bn |
| Dec 31, 2018 | 8.00 Bn |
| Sep 30, 2018 | 8.96 Bn |
| Jun 30, 2018 | 6.82 Bn |
| Mar 31, 2018 | 3.08 Bn |
| Dec 31, 2017 | 6.54 Bn |
| Sep 30, 2017 | 3.72 Bn |
| Jun 30, 2017 | 3.07 Bn |
| Mar 31, 2017 | 2.62 Bn |
| Dec 31, 2016 | 4.58 Bn |
| Sep 30, 2016 | 3.49 Bn |
| Jun 30, 2016 | 3.24 Bn |
| Mar 31, 2016 | 2.31 Bn |
| Dec 31, 2015 | 3.67 Bn |
| Sep 30, 2015 | 3.24 Bn |
| Jun 30, 2015 | 3.32 Bn |
| Mar 31, 2015 | 3.06 Bn |
| Dec 31, 2014 | 3.87 Bn |
| Sep 30, 2014 | 3.17 Bn |
| Jun 30, 2014 | 3.77 Bn |
| Mar 31, 2014 | 3.89 Bn |
| Dec 31, 2013 | 3.83 Bn |
| Sep 30, 2013 | 4.37 Bn |
| Jun 30, 2013 | 3.79 Bn |
| Mar 31, 2013 | 3.94 Bn |
| Dec 31, 2012 | 4.02 Bn |
| Sep 30, 2012 | 5.32 Bn |
| Jun 30, 2012 | 4.35 Bn |
| Mar 31, 2012 | 4.12 Bn |
| Dec 31, 2011 | 5.92 Bn |
| Sep 30, 2011 | 6.60 Bn |
| Jun 30, 2011 | 6.11 Bn |
| Mar 31, 2011 | 6.51 Bn |
| Dec 31, 2010 | 5.99 Bn |
| Sep 30, 2010 | 5.91 Bn |
| Jun 30, 2010 | 5.16 Bn |
| Mar 31, 2010 | 4.73 Bn |
| Dec 31, 2009 | 4.46 Bn |
| Sep 30, 2009 | 3.85 Bn |
| Jun 30, 2009 | 3.32 Bn |
| Mar 31, 2009 | 3.31 Bn |